Roche's quarterly released last week indicated Tamiflu sales in Japan of AUD$73 million. Based on Lani having a slight market lead, we'd get around $3 million in royalties.
It's interesting to note Tamiflu was Roche's 5th best revenue generator worldwide for the quarter. Not bad for a mature product.
- Forums
- ASX - By Stock
- tamiflu potential dud?
Roche's quarterly released last week indicated Tamiflu sales in...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & MD
Charles Armstrong
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online